Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP has reduced its position in Alnylam Pharmaceuticals by 68.0%, owning 11,914 shares valued at $3,217,000 after selling 25,267 shares during the 1st quarter.
• Multiple institutional investors have increased their holdings in Alnylam, with Vanguard Group boosting its stake by 2.5%, and GAMMA Investing LLC making a significant increase of 30,759.4%.
• Alnylam Pharmaceuticals reported a quarterly earnings per share (EPS) of $0.32, which exceeded analysts' expectations, alongside a revenue of $773.69 million, marking a 17.3% increase compared to the previous year.

Voleon Capital Management LP decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 68.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,914 shares of the biopharmaceutical company's stock after selling 25,267 shares during the quarter. Voleon Capital Management LP's holdings in Alnylam Pharmaceuticals were worth $3,217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Whipplewood Advisors LLC raised its position in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. raised its position in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Finally, Washington Trust Advisors Inc. raised its position in Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Piper Sandler upped their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective for the company in a research report on Monday, August 4th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $421.28.

Insiders Place Their Bets

In other news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the sale, the director directly owned 775 shares in the company, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,594 shares of company stock worth $33,968,256. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded down $2.69 during trading hours on Friday, reaching $465.89. The company had a trading volume of 630,774 shares, compared to its average volume of 1,113,410. The firm has a 50 day simple moving average of $401.46 and a 200-day simple moving average of $317.35. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a market capitalization of $61.07 billion, a price-to-earnings ratio of -188.62 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business's revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.